Peter Hsin, BS, discusses a meta-analysis linking perioperative ketamine to lower early postpartum depressive symptoms after cesarean delivery.
|Articles|March 14, 2013
Calendar
Author(s)OBGYN.net Staff
Advertisement
- The 5th IVI International Congress: Reproductive Medicine and Beyond by ComtecMed
04-Apr-13 to 06-Apr-13 Seville , SPAIN (GYN - Contraception & Reproductive Health)
- 2013 AIUM Annual Convention by American Institute of Ultrasound in Medicine
06-Apr-13 to 10-Apr-13 New York (New York Marriott Marquis Hotel) , NY USA (CME - Medical Education)
- Manejo clnico y teraputico de la esterilidad. Segundo curso online by Fundacio Dexeus Salud de la Mujer
09-Apr-13 to 31-May-13 online , SPAIN(gynecology)
- Pediatric Nursing: Care of the Hospitalized Child by Continuing Education Inc.
10-Apr-13 to 13-Apr-13 Anaheim (Hyatt Regency Orange County) , CA USA (CME - Obstetrics, Gynecology & Women's Health)
- Medicina fetal Curso-Taller. Curso de Nivel I y II de la SESEGO by Fundacio Dexeus Salud de la Mujer
15-Apr-13 to 17-Apr-13 Barcelona (Auditorio Salud de la Mujer Dexeus) , SPAIN (OB - Maternal Fetal Medicine)
- Female Urology & Urogynecology Symposium (FUUS) by Quadrant HealthCom, Inc
18-Apr-13 to 20-Apr-13 Las Vegas (ARIA) , NV USA (CME - Obstetrics, Gynecology & Women's Health)
- Female Urology and Urogynecology Symposium (FUUS) 2013 by Quadrant HealthCom, Inc
18-Apr-13 to 20-Apr-13 Las Vegas (ARIA) , NV USA (CME - Obstetrics, Gynecology & Women's Health)
Advertisement
Related to this article
A recap of the top video interviews from Contemporary OB/GYN's coverage of The Menopause Society 2026 Annual Meeting in San Diego.
Susan Reed, MD, MPH, MS, and Calbeth C. Alaribe, DMSc, MPH, PA-C, CPCHE, weigh in on FDA boxed warning removals for menopausal hormone therapy.
The FDA granted accelerated approval to Voceryq to reduce papilloma excision surgeries in adults with recurrent respiratory papillomatosis.
A recap of the top women's health headlines from October 2026, including FDA approval of pritelivir for refractory HSV, ACOG's new menopause guideline, and more.
Chrisandra Shufelt, MD, on using a cardiovascular risk score to guide hormone therapy candidacy at menopause.
The October 30 update from the FDA follows the February 12, 2026 labeling changes to 6 menopausal hormone therapy products in which the agency also removed safety-related boxed warnings.
Neither maternal MOUD dose nor umbilical cord opioid levels were associated with neonatal opioid withdrawal syndrome severity.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
FDA removes boxed warnings from 3 more menopausal hormone therapy products
2
Choosing Among Hormonal and Nonhormonal VMS Therapies in Menopause
3
Reactions to FDA's boxed warning removals for menopausal hormone therapy
4
Top headlines in women's health from October 2026
5